Table 1.
Baseline characteristics (n = 95) of participants who completed the Parkinson's disease Comprehensive Care Clinic (January 2010 to July 2013)
| Characteristic | No. (%) or mean ± SD |
|---|---|
| All patients | 95 (100) |
| Sex | |
| Men | 57 (60.0) |
| Women | 38 (40.0) |
| Race | |
| Caucasian or white | 71 (74.7) |
| African‐American or black | 12 (12.6) |
| Unreported or unavailable | 12 (12.6) |
| Marital status | |
| Single | 24 (25.3) |
| Married | 67 (70.5) |
| Unreported or unavailable | 4 (4.2) |
| Medications at CCC visit | |
| l‐dopa | 86 (90.5) |
| Dopamine agonist | 30 (31.6) |
| COMT inhibitor | 13 (13.7) |
| MAO B blocker | 13 (13.7) |
| Amantadine | 6 (6.3) |
| Acetylcholinesterase inhibitor | 12 (12.6) |
| On none of these | 3 (3.2) |
| Age, y | 68.28 [38–97], n = 95 |
| Duration of PD, y | 7.63 [0–22], n = 91 |
| UPDRS‐III score | 23.84 [3–72], n = 82 |
| MOCA score | 22.85 [3–30], n = 72 |
SD, standard deviation; l‐dopa, levodopa; COMT, catechol‐O‐methyl transferase; MAO, monoamine oxidase B; PD, Parkinson's disease; UPDRS‐III, Unified Parkinson's Disease Rating Scale, motor part; MOCA, Montreal Cognitive Assessment.